Crossmark

Impact of an oncology urgent care center on preventable emergency department visits: revisiting lessons from a global pandemic to improve quality of care

Crossref DOI link: https://doi.org/10.1007/s00520-025-10183-8

Published Online: 2025-12-03

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Russell, Brian M.

O’Donoghue, Ashley L.

Dechen, Tenzin

Lee, Emma M.

Peters, Mary Linton B.

Sato-DiLorenzo, Aya

Shea, Meghan E.

Weinstock, Matthew J.

Stevens, Jennifer P.

Zerillo, Jessica A.
License Information

Text and Data Mining valid from 2025-12-03

Version of Record valid from 2025-12-03
More Information

Article History

Received: 2 July 2025

Accepted: 11 November 2025

First Online: 3 December 2025

Declarations

:

: B.M.R. reports funding from EMD Serono. M.L.P. reports funding from the National Cancer Institute (K08CA248473) as well as institutional research funding from Taiho Pharmaceuticals, AstraZeneca, Nucana, Lilly, Helsinn Therapeutics, and Genentech. M.E.S reports serving on advisory boards for AstraZeneca, Eisai, Genmab, AbbVie, and GSK. A.L.O., A.S.D., E.M.L., T.D., M.J.W., J.P.S. and J.A.Z. do not report any relevant conflicts of interest.

Document is current

Any future updates will be listed below